|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry.
|
31787484 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abiraterone withdrawal syndrome (AWS) is characterized by a transient decrease in the PSA after abiraterone acetate (AA) treatment discontinuation in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
|
31060755 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-377,202 prodrug (Dox-PSA) was in phase I clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
30802065 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
|
30729312 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
|
30980027 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
|
31092441 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
|
30279582 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
|
30099821 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
|
29305637 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate.
|
30194199 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite palliative benefits and PSA responses, the objective clinical impact of daily oral prednisone (P) for metastatic castration-resistant prostate cancer (mCRPC) is unknown.
|
27670718 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA response, PSA progression-free survival (PSA-PFS) and overall survival (OS) from mCRPC to death were analyzed using Kaplan-Meier curves, Log-rank test, Cox regression models and Harrell's C-index.
|
28903426 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.
|
28614217 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy-naive asymptomatic or mildly symptomatic men (n=872) with metastatic castration-resistant prostate cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide in the PREVAIL study were analyzed post hoc for rising versus nonrising PSA (empirically defined as >1.05 vs ⩽1.05 times the PSA level from 3 months earlier) at the time of radiographic progression.
|
28117385 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study identified prognostic factors for OS and PSA response of men with mCRPC treated with cabazitaxel.
|
29290963 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
|
28371163 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current platform expressing multiple costimulatory molecules plus a tumor-associated antigen such as PSA, that is, PSA-TRICOM (PROSTVAC-V/F), is promising and is currently in a Phase III randomized, placebo-controlled clinical trial in metastatic castration-resistant prostate cancer.
|
22413824 |
2012 |